Overview

GEM vs GEM+TS-1 for Advanced Pancreatic Cancer

Status:
Completed

Trial end date:
2010-12-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to compare tumor response rate of the test arm(gemcitabine+S-1) with the control arm(gemcitabine alone) in patients with unresectable pancreatic cancer

Phase:

Phase 2

Details

Lead Sponsor:

Japan Clinical Cancer Research Organization

Treatments:

Gemcitabine